Time filter

Source Type

Liu H.,North Carolina State University | Zheng Y.,ProMetic BioSciences Inc. | Gurgel P.V.,ProMetic BioSciences Inc. | Carbonell R.G.,North Carolina State University
Journal of Membrane Science | Year: 2013

Nonwoven fabrics are of great interest as potential materials for bioseparations due to their interconnected porous structure, relatively high surface area and low cost. In this paper we focus on the development of a potentially disposable affinity membrane for pathogen removal from biological systems such as human plasma. Poly glycidyl methacrylate (polyGMA) was grafted on the fiber surface of a polybutylene terephthalate (PBT) nonwoven using photo-induced graft polymerization. SEM and FTIR were used to characterize the pore structure and surface chemistry of the resulting material. To minimize nonspecific protein binding and hydrophilize the material, diethylene glycol (DEG) and diol groups were attached covalently to the grafted layer of polyGMA. The amount of nonspecific binding was quantified by the adsorption of bovine serum albumin (BSA) and an E. coli extract. The results showed that the grafted matrix containing DEG or diol groups bound significantly less total protein, compared with unmodified material. The DEG modified membrane was further developed by attachment of a specific proprietary ligand that binds to the prion protein, the agent responsible for transmissible spongiform encephalopathies. The affinity membrane showed good selectivity for the capture of prion protein from hamster brain homogenate. © 2012 Elsevier B.V.


Zheng Y.,ProMetic BioSciences Inc. | Gurgel P.V.,ProMetic BioSciences Inc. | Carbonell R.G.,North Carolina State University
Industrial and Engineering Chemistry Research | Year: 2011

This paper describes the spatial uniformity of grafted layers of poly(glycydyl methacrylate) on the fibers of polypropylene nonwoven fabrics, and how they depend on the UV pretreatment step, the adsorption of initiator (benzophenone) to the fiber surface, and the UV grafting step. UV light transmission inside the nonwoven fabrics was measured to determine the effect of light intensity variations during the pretreatment and grafting steps. The light intensity decay depends on the pore size of the fabric and the presence of solvents in the nonwoven fabric. The adsorption of benzophenone to the fiber surface is lower in regions of low light intensity, resulting in a spatial variation due to the UV pretreatment. The presence of solvents tends to reduce light intensity decay during the grafting step. The results of this paper indicate how to avoid spatial nonuniformities during grafting by controlling the reaction conditions. © 2011 American Chemical Society.


Patent
ProMetic BioSciences Inc. | Date: 2013-02-28

A method is disclosed for the preparation of glycerol esters (triglycerides) of medium-chain length monocarboxylic fatty acids which consists of the reaction of the precursor free fatty acid and glycerol in the presence of a catalyst under partial vacuum. The process preferably uses a metal catalyst such as an oxide or a chloride of tungsten, molybdenum, calcium, zinc, chromium or magnesium. The method of the invention allows the preparation in high yield and high purity (>99.5%) of the final triglyceride. The present method allows the formation of triglycerides without solvent. Are also contemplated, the triglyceride obtained by the method, and the pharmaceutical composition containing the triglyceride as an excipient or as an active ingredient.


Patent
ProMetic BioSciences Inc. | Date: 2011-10-26

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil.


Patent
ProMetic BioSciences Inc. | Date: 2014-12-08

The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders.


The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein A is C_(5 )alkyl, C_(6 )alkyl, C_(5 )alkenyl, C_(6 )alkenyl, C(O)(CH_(2))_(n)CH_(3 )or CH(OH)(CH_(2))_(n)CH_(3 )wherein n is 3 or 4; R_(1 )is H, OH or F; R_(2 )is H, OH, F or CH_(2)OH; R_(3 )is H, OH, F or CH_(2)Ph; R_(4 )is H, OH or F; Q is 1) (CH_(2))_(m)C(O)OH wherein m is 1 or 2, 2) CH(CH_(3))C(O)OH, 3) C(CH_(3))_(2)C(O)OH, 4) CH(F)C(O)OH, 5) CF_(2)C(O)OH, or 6) C(O)C(O)OH.


Patent
ProMetic BioSciences Inc. | Date: 2014-03-14

The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C_(5 )alkyl, C_(6 )alkyl, C_(5 )alkenyl, C_(6 )alkenyl, C(0)-(CH_(2))n-CH_(3 )or CH(OH)(CH_(2))n-CH_(3 )wherein n is 3 or 4; R_(1 )is H, F or OH; R_(2 )is C_(5 )alkyl, C_(6 )alkyl, C_(5 )alkenyl, C_(6 )alkenyl, C(0)-(CH_(2))n-CH_(3 )or CH(OH)(CH_(2))n-CH_(3 )wherein n is 3 or 4; R_(3 )is H, F, OH or CH_(2)Ph; R_(4 )is H, F or OH; Q is 1) (CH_(2))_(m)C(0)OH wherein m is 1 or 2, 2) CH(CH_(3))C(0)OH, 3) C(CH_(3))_(2)C(0)OH, 4) CH(F)C(0)OH, 5) CF_(2)-C(0)OH, or 6) C(0)-C(0)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.


Patent
ProMetic BioSciences Inc. | Date: 2015-07-13

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil.


Patent
ProMetic BioSciences Inc. | Date: 2011-10-26

Phenylketone carboxylate compounds of Formula I, wherein n=2-6; RC(0); OC(O) or CH(OH); A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction.


Patent
ProMetic BioSciences Inc. | Date: 2011-10-26

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I, IA, IB and IC, and their pharmaceutical acceptable salts are described for prevention or treatment of diabetes or a diabetes-related disorder in a subject in need thereof. Diabetes and diabetes-related disorder include Type I diabetes, Type II diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes of adults (LADA), gestational diabetes, diabetic nephropathy, proteinuria, ketonuria, obesity, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, metabolic syndrome, syndrome X, diabetic neuropathy, diabetic retinopathy, hypoglycemia, cardiovascular disease, atherosclerosis, diabetic kidney disease, ketoacidosis, thrombotic disorders, sexual dysfunction, dermatopathy, edema, metabolic syndrome and renal disorders. The related pharmaceutical compositions and methods are also described. These compounds can be used in combination with comprising a therapeutic agent for lowering or controlling blood glucose level such as metformin or a thiazolidinedione.

Loading ProMetic BioSciences Inc. collaborators
Loading ProMetic BioSciences Inc. collaborators